Find Funding Opportunities

The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate Clinical Trials Required or Clinical Trial Optional FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).

The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers.

The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers.

The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers.

Notice Special Interest NOSI): Availability Urgent Competitive Revisions Administrative Supplements Research Biological Effects the 2019 Novel Coronavirus the Nervous System Notice Number: NOT-NS-20-051 Key Dates Release Date: April 30, 2020 First Available Due Date: 01, 2020 Expiration Date: April 15, 2021 Related Announcements NOT-NS-20-074 Notice Change Eligible Activity Codes NOT-NS-20-051 PA-18-935 Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement - Clinical Trial Optional) PA-18-591 Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) NOT-OD-20-026 New NIH FORMS-F" Grant Application Forms Instructions Coming Due Dates or after 25, 2020 Issued National Institute Neurological Disorders Stroke NINDS) National Institute Alcohol Abuse Alcoholism NIAAA) - New participating organization of 05/08/2020 due dates on/after 05/08/2020 Purpose NINDS issuing Notice Special Interest NOSI) highlight urgent need research Coronavirus Disease 2019 COVID-19) on biological effects the nervous system its causative agent, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2). Research interest must fall within NINDS’s scientific mission, is support basic, translational, clinical neuroscience research expand fundamental knowledge the brain nervous system to that knowledge reduce burden neurological disease. Research Objectives order rapidly improve our understanding the neurological consequences infection SARS-CoV-2 of COVID-19, NINDS encouraging submission applications supplements address biology, pathophysiology, prevention, diagnosis, sequelae, treatment the 2019 Novel Coronovirus are directly related the NINDS mission. National Institute Alcohol Abuse Alcoholism NIAAA) accept supplements NIAAA-supported projects fall within scope the NOT-NS-20-051 are relevant the mission the NIAAA. Specifically, NIAAA interested studies integrate alcohol exposure research topics outlined the announcement better understand, prevent, mitigate of neurobiological consequences SARS-CoV-2 infection COVID-19 individuals have Alcohol Disorders AUD). NIAAA encourages supplements be collaborative nature include appropriate neurological expertise the proposed projects. Application Submission Information Applications this initiative must submitted using of following opportunity announcements the subsequent reissued equivalent. PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) PA-18-935 - Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement - Clinical Trial Optional) Applications research fall within scope an existing NINDS award should submitted through PA-18-591 (Parent Admin Supp Clinical Trial Optional). Eligible activity codes fare limited the mechanisms listed in PA-18-591. Applications research involve change the original scope an active award, still falls within mission the NINDS must apply through PA-18-935 Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement - Clinical Trial Optional). Eligible activity codes applications to PA-18-935 are limited the following mechanisms: P01, P50, R00, R01, R03, R15, R21, R33, R35, R41, R42, R43, R44, R61, U01, U19, U24, U44, U54, UG3, UH3). Scope defined the original specific aims, objectives, purposes a grant, methodology, approach, analyses other activities, the tools, technologies, timeframes needed meet grant's objectives. Changes include shifting research emphasis one disease area another, changing any aspects research involving vertebrate animals human subjects. you unsure whether application involve change scope, contact NINDS program director. instructions the SF424 R&R) Application Guide and PA-18-591 or PA-18-935 must followed, the following additions: funding consideration, applicants must include “NOT-NS-20-051"(without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. project period the supplement must exceed year. Application budgets not exceed 200,000 direct costs. Exceptions this budget limit be only NINDS pre-approval will only approved under very rare circumstances where work immediately impact public health. Research Strategy section the application limited 6 pages parent award must active the supplement application submitted e.g. within originally reviewed approved project period), regardless the time remaining the current project. Grants multi-year funding RF1) have additional constraints. Applicants these grants should contact program official determine eligibility. applications including those multi-project activity codes) must submitted electronically using single-project application form package Administrative supplement applications to PA-18-591 must the application form package the Competition ID contains FORMS-E-ADMINSUPP”. FOA be reissued application form packages containing FORMS-F-ADMINSUPP” May 25, 2020. Submissions to PA-18-591 must completed June 25, 2020 see NOT-OD-20-026 for details.) Submissions the reissued FOA be accepted or after 25, 2020 through expiration date this Notice. addition, process Streamlined Submissions using eRA Commons cannot used this initiative. Competitive revision applications to PA-18-935 must the application form package the Competition ID NOT-NS-20-051-FORMS-E." FOA be reissued a NOT-NS-20-051-FORMS-F” package May 25, 2020. Submissions to PA-18-935 must completed June 25, 2020. Submissions the reissued FOA be accepted or after 25, 2020 through expiration date this Notice. Applications be accepted a rolling basis from April 15, 2020 April 14, 2021 5:00 PM local time of applicant organization. NOSI expires on April 15, 2021. application submitted response this NOSI is received after expiration date be withdrawn Applications must specifically address issues potential biohazards, all research must conducted compliance the health safety requirements found the NIH Grants Policy Statement. Applications are responsive the terms this Notice not considered. Investigators planning apply response this NOSI strongly encouraged contact discuss proposed research/aims the Program Official the Parent Award advance better determine appropriateness interest the NINDS.   Inquiries Please direct inquiries the contacts Section VII the listed funding opportunity announcements the following additions/substitutions: Scientific/Research Contact(s) Please contact program officer your active award. NIAAA grantees, please direct inquiries Dr. Changhai Cui changhai.cui@nih.gov).

HEAL Initiative: Notice Special Interest NOSI) regarding Availability Administrative Supplements Support Strategies Reduce Stigma Pain Management Opioid Disorder OUD) Treatment Notice Number: NOT-OD-20-101 Key Dates Release Date: April 23, 2020 First Available Due Date: 29, 2020 Expiration Date: 30, 2020 Related Announcements PA-18-591 Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) Issued Office Behavioral Social Sciences Research OBSSR) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Dental Craniofacial Research NIDCR) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Drug Abuse NIDA) National Institute Neurological Disorders Stroke NINDS) National Center Complementary Integrative Health NCCIH) National Cancer Institute NCI) applications this funding opportunity announcement should fall within mission the Institutes/Centers. following NIH Offices co-fund applications assigned those Institutes/Centers. Division Program Coordination, Planning Strategic Initiatives, Office Disease Prevention ODP) Office Research Women's Health ORWH) Purpose Notice Special Interest NOSI) calls research stigma the context chronic pain management opioid or opioid disorder OUD). part NIH’s Helping End Addiction Long Term HEAL) Initiative, NIH support supplements current HEAL awards address challenges people affected the opioid crisis stigma, discrimination prejudice related chronic pain management the context opioid and/or opioid disorder its treatment. NOSI calls applications integrate incorporate stigma research ongoing HEAL funded chronic pain OUD studies order address stigma is occurring the context chronic pain and/or OUD. Because stigma research require large clinical community networks, supplement program designed leverage many networks already being developed through HEAL awards. supplement program not intended support research basic processes e.g. cultural attitudes) rather result strategies enable rapid implementation changes. total up 3.5 million available supplement existing HEAL grants cooperative agreements, up 1 year, evaluate strategies reduce stigma improve treatment, management services people chronic pain and/or OUD. Supplement requests not need address possible aspects stigma the context chronic pain or OUD, it encouraged appropriate consider piloting multi-layer, multicomponent interventions address stigma these contexts. Background 50 million adults the United States chronic daily pain. 19.6 million adults experience chronic pain interferes daily life work activities. Misuse addiction opioids, including prescription pain relievers, synthetic opioids such fentanyl, heroin become serious national health crisis. than130 people die every day an opioid-related drug overdose. Stigma be barrier treatment both people chronic pain the context being treated opioids also people OUD related painful conditions. Appropriate care needed address suffering people pain and/or OUD it critical address challenges associated stigma living these conditions, seeking care support pain management and/or recovery OUD. Stigma be barrier treatment both painful conditions substance abuse. Studies suggest people chronic pain are receiving who previously received opioid treatment face stigma their healthcare providers, family, friends, coworkers, health care system, society general. Stigma also major barrier implementation programs treatments chronic pain opioid disorder, such medication assisted treatment naloxone. People chronic pain problematic opioid report significant perceived stigma associated methadone buprenorphine treatment. Stigma also lead severe consequences people chronic pain long term opioid face acute opioid withdrawal due stigma. Chronic pain often stigmatized itself some approaches address opioid crisis led stigma related addictions be also applied people chronic pain. Stigma be challenge people pain and/or substance disorders, families, caregivers, clinicians. Reducing barriers care exist because stigma crucial care people for treatment effectiveness both chronic pain management and/or OUD. Research Objectives order effectively reduce stigma related the treatment chronic pain the context the opioid crisis and/or stigma related OUD, NIH encouraging submission applications supplements active grants provide evidence-based data inform strategies reduce stigma build resilience discrimination those chronic pain and/or OUD. High priority supplements will: Analyze strategies reduce stigma, discrimination prejudice related chronic pain management and/or OUD impact areas such prevention, management treatment access effectiveness recovery; existing psychometrically validated tools measure stigma only very compelling rationales, support development any new measurement tool. Research areas interest include: Prejudice care providers undermine treatment health QOL Strategies address stigma a variety contexts includes: among healthcare providers, workplace colleagues, emergency responders, family friends others; impact internalized anticipated stigma prevention, management, treatment recovery; adaption application existing theories health related stigma chronic pain and/or OUD reducing stigma; Rather the creation new measurement tools, use psychometrically validated measures stigma other populations e.g. HIV, mental illness) their application these populations. Analyses combinations approaches are known reduce discrimination prejudice a variety situations workplace- supervisors, colleagues; family friends, healthcare providers, emergency responders, community); Strategies address internalized stigma; Approaches build resilience discrimination prejudice these populations First stage development multicomponent approaches could expanded implemented large scale multicomponent research projects. Researchers find materials related the 2017 meeting: The Science Stigma Reduction that sponsored the National Institutes Health NIH) helpful. Description circumstances which administrative supplements available. Application Submission Information Applications this initiative must submitted using following opportunity its subsequent reissued equivalent. PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) instructions the SF424 R&R) Application Guide and PA-18-591 must followed, the following additions: Application Due Date(s) – Applications be accepted through 29 , 2020 , 5:00 PM local time applicant organization. NOSI expires May 30 , 2020 funding consideration, applicants must include ldquo;NOT-OD-20 101” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Requests be one year support only. Research Strategy section the application limited 6 pages. parent award must active the application submitted. project budget periods must within currently approved project period the existing parent award. Applications non-responsive the terms this Notice be be considered this initiative. Review criteria, addition those described PA-18-591, include following: Does PI(s)/PD(s) expertise stigma, pain management and/or addiction appropriate the study stigma chronic pain opioid use? Does application propose engage people chronic pain and/or those OUD, providers, relevant stakeholders identifying key questions regarding stigma chronic pain management opioid and treatment? successful, does application the potential be implemented broadly Administrative supplement applications to PA-18-591 must the application form package the Competition ID contains ldquo;FORMS-F-ADMINSUPP”. addition, process Streamlined Submissions using eRA Commons cannot used this initiative. Investigators planning submit application response the NOSI strongly encouraged contact appropriate Institute Center contact listed the NOSI discuss proposed project the context the parent award. Questions specific this NOSI should sent the contact listed the NOSI. nbsp; Inquiries Please direct inquiries to: Wendy B. Smith, MA, PhD, BCBAssociate DirectorOffice Behavioral Social Sciences Research OBSSR)Tel: 301-435-3718Email: smithwe@mail.nih.gov Wendy Weber, N.D., PhD., MPHNational Center Complementary Integrative Health NCCIH)Tel: 301-402-1272Email: mailto:weberwj@mail.nih.gov Alexis Bakos, PhD., MPH., RN National Cancer Institute NCI)Tel: 240-276-6609Email: alexis.bakos@nih.gov Leslie K. Derr, Ph.D.National Institute Arthritis Musculoskeletal Skin Diseases NIAMS)Tel: 301-402-4735 Email: derrl@mail.nih.gov M. Aklin, Ph.D.National Institute Drug Abuse NIDA)Tel: 301-827-5909Email: aklinwm@nida.nih.gov Shelley Su, Ph.D.National Institute Drug Abuse NIDA)Tel: 301-402-3869Email: shelley.su@nih.gov Yolanda Vallejo, PhD.National Institute Dental Craniofacial Research NIDCR)Tel: 301-827-4655Email: Yolanda.Vallejo@nih.gov Paul L. Kimmel, MDNational Institute Diabetes Digestive Kidney Diseases NIDDK)Tel: 301-594-1409Email:  Kimmelp@mail.nih.gov Durga Mohapatra, Ph.D.National Institute Neurological Disorders Stroke NINDS)Tel: 301-827-7403Email: dp.mohapatra@nih.gov Jacqueline Lloyd, PhD, MSWOffice Disease Prevention ODP)Tel: 301-827-5559Email: lloydj2@nih.gov

The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA

The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA